A Phase 2 interventional study of Qurse Revand and Placebo in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), sponsored by National Institute of Unani Medicine, Bengaluru. Not yet recruiting at 1 site in India. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by National Institute of Unani Medicine, Bengaluru · Phase 2, Interventional, and Treatment
This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, efficacy of the Unani compound formulation Qurse Revand compared to a placebo in adult participants with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
This randomized, double-blind, placebo-controlled clinical trial evaluates the safety, efficacy, and quality-of-life impact of the Unani formulation Qurse Revand in 128 adults (aged 20-60) with Grade I or II Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Participants take either Qurse Revand (3 tablets of 835 mg) or a matching wheat flour placebo twice daily before meals for 60 days alongside a Mediterranean diet and 30 minutes of daily brisk walking 5 days per week. Throughout the trial, participants visit the clinic every 15 days-at Baseline (Day 0) and Follow-ups on Days 15, 30, 45, and 60-to undergo physical examinations, abdominal ultrasonography, liver and kidney function tests, lipid profiles, hematological evaluations, symptom tracking, and quality-of-life assessments (EQ-5D).
National Institute of Unani Medicine, Bengaluru is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with Presence of at least 1or more cardiometabolic risk factor
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (Wheat flour)
Drug: Placebo
Qurse Revand
Drug: Qurse Revand
Qurse Revand (3 tablets of 835 mg each) twice daily before meals for 60 days
placebo (wheat flour) (3 tablets of 835 mg each) twice daily before meals for 60 days,
Change in Fatty Liver Grading by USG
Changes /decrease in fatty liver grading(from grade 1,2 to grade 0,1)by USG
Time frame: From enrollment to the end of treatment at 60 Days
Change in Fatty Liver Index (FLI)
Change/Decrease in fatty liver Index. FLI calculates a score ranging from 0 to 100 using four routinely measured parameters. FLI Score Interpretation: (FLI \< 30 = Low Probability, 30 ≤ FLI \< 60 =Intermediate / Indeterminate, FLI ≥ 60= High Probability )
Time frame: From enrollment to the end of treatment at 60 days
Change in Lipid Profile
Change in serum Triglycerides levels(mg/dL or mmol/L) \&Change in serum High-Density Lipoprotein (HDL) Cholesterol(mg/dL or mmol/L)
Time frame: From enrollment to the end of treatment at 60 days
Changes in Health-related quality of life using EuroQol-5D (EQ-5D)
The EQ-5D consists of two main components: 1. EQ-5D Index Score (Utility Score): How it is calculated: The combinations from the 5 dimensions are converted into a single summary index using population-specific country value sets. Scale Range: Typically spans from 1.0 (Full/Perfect Health) to 0.0 (A state equivalent to death). Negative values are possible for health states valued as worse than death. 2. EQ Visual Analogue Scale (EQ-VAS): A 0-100 rating scale measuring overall perceived health (100 = best,0 = worst).
Time frame: From enrollment to the end of treatment at 60 days
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2027; primary completion for May 2029, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Unani Medicine, Bengaluru